Changjiang Life Science (00775) rose by nearly 30%. As of press release, it rose 21.88% to HK$0.39, with a turnover of HK$13.1371 million.
The Zhitong Finance App learned that Changjiang Life Technology (00775) rose by nearly 30%. As of press release, it had risen 21.88% to HK$0.39, with a turnover of HK$13.1371 million.
According to the news, Changjiang Life Technology announced that at the AACR 2024 conference, the company will present new pre-clinical research data on two sets of research cancer vaccines targeting rat sarcoma virus cancer gene (KRAS) and cellular programmatic death-ligand 1 (PD-L1), respectively. At the same time, the company will work with partner Jingtai Technology to show how its artificial intelligence-driven (AI) platform can be used to design cancer vaccines.
The company believes that the preclinical efficacy results of the investigational cancer vaccine against KRAS and PD-L1 protein are encouraging, and the company hopes to advance these vaccines and other vaccines to the clinical research stage in the future. The company is also pleased with the progress of the research collaboration with XtalPi. The AI platform developed by this collaborative project aims to help predict immunogenicity more accurately and design or more effective cancer vaccines.